VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. The company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for Short Bowel Syndrome.
View Top Employees from VectivBio AGWebsite | https://vectivbio.com/ |
Ticker | VECT |
Employees | 66 (66 on RocketReach) |
Founded | 2019 |
Address | 36 Aeschenvorstadt, Basel, Basel-City 4051, CH |
Phone | +41 61 551 30 30 |
Technologies |
JavaScript,
HTML,
PHP
+24 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Drug Discovery |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541713 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies |
Looking for a particular VectivBio AG employee's phone or email?
Christian Meyer is the COO of VectivBio AG.
66 people are employed at VectivBio AG.
VectivBio AG is based in Basel, Basel-City.
The NAICS codes for VectivBio AG are [541, 54171, 541713, 54, 5417].
The SIC codes for VectivBio AG are [873, 87].